Harbin Medisan Stock Soars 10.01%, Hits Intraday High of CNY 14.83

Harbin Medisan Pharmaceutical Co., Ltd. has experienced a significant surge in its stock price, gaining 10.01% on August 10, 2026. The stock reached an intraday high of CNY 14.83, marking a notable performance against the backdrop of the China Shanghai Composite, which only increased by 0.67% on the same day. Over the past week, Harbin Medisan has shown impressive momentum, with a 31.59% rise, while its one-month performance stands at 51.33%. However, the company has faced challenges in the longer term, with a one-year decline of 3.89% and a five-year drop of 42.52%. Despite these setbacks, the year-to-date performance reflects a positive trend, with a 19.02% increase. The small-cap pharmaceutical company operates in a competitive industry, and its market capitalization is currently CNY 2,450 million. Key financial metrics indicate a low return on equity of -17.46% and a debt-to-equity ratio of 0.33. As Harbin Medisan continues to navigate its financial landscape, today's performance highlights its current volatility and market activity.